Clinical Trial Update: A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of ASG-5ME for pancreatic and gastric adenocarcinoma has completed. The snippet does not include results or efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Pancreatic Cancer

Drugs mentioned

• ASG-5ME (ASG-5ME)

Snippet

Sponsor: Seagen Inc. | Conditions: Gastric Neoplasms, Pancreatic Neoplasms | Phase 1 | Status: COMPLETED